<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>321</serviceExecutionTime><Drug id="69802"><DrugName>alendronate sodium hydrate (hypercalcemia), Teijin</DrugName><DrugNamesKey><Name id="42945000">Teiroc</Name><Name id="42753369">alendronic acid</Name></DrugNamesKey><DrugSynonyms><Name><Value>alendronate sodium hydrate</Value></Name><Name><Value>alendronic acid</Value><Types><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>alendronate sodium hydrate (hypercalcemia), Teijin</Value></Name><Name><Value>Teiroc</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>alendronic acid (hypercalcemia), Teijin</Value></Name><Name><Value>121268-17-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>66376-36-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20331">Teijin Ltd</CompanyOriginator><CompaniesPrimary><Company id="20331">Teijin Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="20331" type="Company"><TargetEntity id="4295877394" type="organizationId">Teijin Ltd</TargetEntity></SourceEntity><SourceEntity id="173" type="ciIndication"><TargetEntity id="E83.52" type="ICD10"></TargetEntity><TargetEntity id="10020583" type="MEDDRA"></TargetEntity><TargetEntity id="D006934" type="MeSH"></TargetEntity><TargetEntity id="-854433067" type="omicsDisease"></TargetEntity><TargetEntity id="968" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hypercalcemia - Japan - Dec-1997</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="173">Hypercalcemia</Indication></IndicationsPrimary><ActionsSecondary><Action id="12596">Osteoclast inhibitor</Action><Action id="484">Calcium metabolism inhibitor</Action><Action id="89">Bone resorption inhibitor</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2015-04-17T15:30:14.000Z</LastModificationDate><ChangeDateLast>2011-01-31T10:49:03.000Z</ChangeDateLast><AddedDate>2011-01-26T09:21:01.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="20331"&gt;Teijin&lt;/ulink&gt; has developed and launched Teiroc, an iv formulation of the bisphosphonate calcium metabolism regulator &lt;ulink linkType="Drug" linkID="2472"&gt;alendronic acid&lt;/ulink&gt; as the sodium salt, indicated in Japan for the treatment of hypercalcemia associated with malignant tumors. The product was launched in Japan in 1997 [&lt;ulink linkType="Reference" linkID="692289"&gt;692289&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1163524"&gt;1163524&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;The product was launched in Japan in 1997 [&lt;ulink linkType="Reference" linkID="692289"&gt;692289&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Teijin licensed the Japanese rights to alendronic acid from &lt;ulink linkType="Company" linkID="16297"&gt;Istituto Gentili&lt;/ulink&gt; (now a subidiary of &lt;ulink linkType="Company" linkID="18077"&gt;Merck &amp;amp; Co&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="190336"&gt;190336&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="173">Hypercalcemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-31T00:00:00.000Z</StatusDate><Source id="692289" type="PR"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]</Smiles><Smiles>C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="150351" number="JP-05607408" title="Alendronic acid containing injection"></PatentFamily><PatentFamily id="1647155" number="JP-03566984" title="Osteogenesis promoter"></PatentFamily><PatentFamily id="23256" number="US-05958908" title="Sodium Alendronate Preparation For Local Administration"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teijin Ltd" id="20331"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>